Clinical trials: Camrelizumab
Advanced Hepatocellular Carcinoma, Lung Cancer
Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma
Ablation has been an effective therapy in treating intrathoracic metastases. However, for hepatocellular carcinoma with pulmonary oligometastasis, ablation of metastases remains relatively unexplored and still needs clinical…
- Conditions
- Advanced Hepatocellular Carcinoma, Lung Cancer, Oligometastasis, Ablation
- Trial name
- NCT06644430
- Testing
- Ablation, system therapy
- Where
- China
- Volunteers
- 470 people
- Sponsor
- Sun Yat-sen University
Gastric Cancer
Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer
This is a prospective, single-center, single-arm, open-label clinical study, aiming at evaluating the efficacy and safety of camrelizumab for injection, apatinib mesylate and tegio for first-line refractory patients with advanced…
- Trial name
- NCT04345783
- Testing
- Camrelizumab for injection, apatinib mesylate and tegio
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Friendship Hospital
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma
Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy
For recurrent or persistent advanced cervical cancer patients, the first-line chemotherapy was based on platinum. However, if they were refractory to platinum-based chemotherapy, there were no other more effective medications or…
- Conditions
- Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemotherapy, Anti-PD-1 Antibody
- Trial name
- NCT04188860
- Testing
- A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Lei Li
TNBC
A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer
Camrelizumab + Chemoradiotherapy for Early TNBC Sponsor/Leading Center: Tianjin Medical University Cancer Institute and Hospital Study Type: Single-arm, single-center, Phase Ⅱ clinical study Planned Enrollment: 43 patients…
- Trial name
- NCT07491822
- Testing
- treatment group
- Volunteers
- 43 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
HER2-negative Breast Cancer, Neoadjuvant Therapy
Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy
The achievement of pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) is associated with improved outcome across all breast cancer (BC) subtypes.
- Conditions
- HER2-negative Breast Cancer, Neoadjuvant Therapy, Pathological Complete Response, Immunotherapy
- Trial name
- NCT04848454
- Testing
- Camrelizumab with vinorelbine and cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University First Hospital
Pancreatic Cancer Stage IV, Pancreatic Cancer Metastatic
A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer
Aim：Evaluate the efficiency and safety of anti-PD1 antibody (Camrelizumab) combined with Paclitaxel(Albumin Bound) and Gemcitabine as first-line therapy in patients with metastatic pancreatic cancer.
- Trial name
- NCT04674956
- Testing
- Camrelizumab, Paclitaxel(Albumin Bound) and Gemcitabine
- Where
- 6 sites in China
- Volunteers
- 401 people
- Sponsor
- RenJi Hospital
Head and Neck Squamous Cell Carcinoma
Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell Carcinoma
This is a prospective, open-labelled study to evaluate the efficacy and safety of Camrelizumab in Combination With Apatinib mesylate Plus Albumin-bound paclitaxel and cisplatin as the First Line Treatment of Metastatic or…
- Trial name
- HNSCC (NCT05189184)
- Testing
- Camrelizumab+Apatinib mesylate+Albumin-bound paclitaxel+cisplatin
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Advanced Solid Tumor
A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors
The purpose of this study is to evaluate the safety of SHR-1702 monotherapy or in combination with Camrelizumab among advanced solid tumor subjects.
- Trial name
- NCT03871855
- Testing
- SHR-1702, Camrelizumab
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Recurrent Glioblastoma
Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)
This study is intend to explore the efficacy and safety of combined treatment of camrelizumab and bevacizumab in adult patients with recurrent glioblastoma.
- Trial name
- NCT04952571
- Testing
- Camrelizumab and Bevacizumab
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Beijing Sanbo Brain Hospital
Endometrial Cancer
Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer
Patients with advanced mismatch repair-deficient (MMRd) or microsatellite instability-high (MSI-H) endometrial cancer (EC) are currently treated as one entity, and immune checkpoint inhibitor (ICI) monotherapy is the treatment of…
- Trial name
- CAN-RESPOND (NCT05550558)
- Testing
- Anlotinib + Camrelizumab
- Volunteers
- 43 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Esophageal Squamous Cell Carcinoma
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma
We plan to conduct a single-center,prospective, Open Label, Randomized Controlled, Phase II Clinical Study of the Combination of Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy in the Treatment of Locally Advanced…
- Trial name
- NCT07312578
- Testing
- Nimotuzumab, camrelizumab, Albumin paclitaxel
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Peking University
Nasopharyngeal Cancinoma (NPC)
Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
We expect to conduct a clinical trial in recurrent and metastatic nasopharyngeal carcinoma patients to explore and compare the efficacy and safety of induction chemotherapy (TPC vs. GP) with combination therapy of Camrelizumab.
- Trial name
- NCT06669611
- Testing
- Camrelizumab combined GP chemotherapy, Camrelizumab combined TPC chemotherapy
- Where
- China
- Volunteers
- 242 people
- Sponsor
- Sun Yat-sen University
Advanced Hepatocellular Carcinoma
Camrelizumab Utilization on Patients With Advanced Liver Cancer
To observe and evaluate the safety and efficacy of camrelizumab in advanced liver cancer
- Trial name
- NCT04487704
- Testing
- camrelizumab
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Hepatocellular Carcinoma, Immune Checkpoint Inhibitors
A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).
The purpose of this study is to observe and preliminary explore the efficacy and safety of the combination of Camrelizumab and Apatinib regimen in treating advanced hepatocellular carcinoma (HCC) participants who have progressed…
- Trial name
- NCT04826406
- Testing
- Camrelizumab combined Apatinib regimen
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Hunan Cancer Hospital
Non-small Cell Lung Cancer
Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC
This study is a single-arm, prospective, multi-center clinical trial. designed to evaluate patients with stage IV inability to receive or refuse chemotherapy.Efficacy and safety of first-line treatment with Camrelizumab and Endo…
- Trial name
- NCT04303130
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Peking University Cancer Hospital & Institute
Osteosarcoma, Survival
Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma
Treatment strategies for high-grade osteosarcoma with multidrug chemotherapy and resection result in 3-year event-free survival of 60-70%.
- Conditions
- Osteosarcoma, Survival, Chemotherapy Effect, Toxicity, Drug
- Trial name
- MAPAC (NCT04351308)
- Testing
- MAPI chemotherapy, Apatinib Mesylate, Camrelizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University People's Hospital
PD-1 Inhibitor, G-CSF
PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure
Recurrence and metastasis are the main causes of treatment failure of NPC. Preliminary clinical studies have found that the overall response rate of PD-1 inhibitors in treating ≥2 line R/M NPC is about 25%.
- Trial name
- NCT05222035
- Testing
- Camrelizumab, G-CSF
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Sun Yat-sen University
Gastric Cancer, GastroEsophageal Cancer
A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
This is a randomized, open-label, multi-center, phase III trial to evaluate the efficacy and safety of SHR-1210 plus capecitabine and oxaliplatin sequenced by SHR-1210 plus apatinib versus capecitabine and oxaliplatin as…
- Trial name
- NCT03813784
- Testing
- SHR-1210, Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 885 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Colorectal Cancer, Microsatellite Instability High
PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer
In this open-label phase II study, patients will be scheduled for neoadjuvant treatment with PD-1 inhibitors (Camrelizumab) plus VEGF inhibitor (Apatinib) for dMMR/MSI-H colorectal cancer staged as locally advanced (cT3-4N+/-M0…
- Trial name
- NCT04715633
- Testing
- PD-1 inhibitor plus VEGF inhibitors
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Sun Yat-sen University
NSCLC
A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC.
This is a phase II, open-label, multi-cohort study, aiming to investigate safety and efficacy of Camrelizumab combined with famitinib for adjuvant treatment of stage II-IIIA non-small cell lung cancer with high-risk for relapse…
- Trial name
- CAMFA-L (NCT05005468)
- Testing
- Camrelizumab, Famitinib
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Shanghai Chest Hospital